BioSpace News Archive

OncoQuest Pharmaceuticals Inc., (“OncoQuest”) a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer, today announces the first patient enrolled in each of two investigator initiated clinical trials assessing the safety and efficacy of oregovomab in a previously treated recurrent ovarian cancer setting.

Cue Health Inc. (“Cue Health” or “Cue”), a health technology company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock.

MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation has announced the appointment of Sharon Gabrielson, Symeria Hudson and David McAllister, MD, to the MTF Biologics Board of Directors.

Aquarius Surgical Technologies Inc. released its financial results for the three-month, first-quarter-period ending June 30, 2021.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird’s 2021 Global Healthcare Conference.

INmune Bio, Inc. announced that XPro™, the Company’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease, treatment resistant depression, and other neurological diseases where neuroinflammation is implicated, has been found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with AD.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on August 31, 2021, the Company granted restricted stock units to one new employee of the Company.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced new executive leadership roles, strengthening its innovation and go-to-market teams while furthering the Company’s growth.

Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that management will present at the following upcoming September 2021 virtual investor conferences.